SELLAS Life Sciences
28 hedge funds and large institutions have $2.68M invested in SELLAS Life Sciences in 2017 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 6 increasing their positions, 8 reducing their positions, and 10 closing their positions.
2,158% more call options, than puts
Call options by funds: $700K | Put options by funds: $31K
0% less ownership
Funds ownership: 0.01% → 0.01% (-0%)
18% less funds holding
Funds holding: 34 → 28 (-6)
25% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 8
41% less capital invested
Capital invested by funds: $4.57M → $2.68M (-$1.89M)
50% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 10
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$242K |
| 2 |
SM
Sabby Management
Miami Beach,
Florida
|
+$25.1K |
| 3 |
TSS
Two Sigma Securities
New York
|
+$15.2K |
| 4 |
CGA
Crescent Grove Advisors
Lake Forest,
Illinois
|
+$8.58K |
| 5 |
VF
Virtu Financial
New York
|
+$8.58K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ECM
Element Capital Management
New York
|
-$93K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$75.2K |
| 3 |
PP
Paloma Partners
Greenwich,
Connecticut
|
-$70K |
| 4 |
LP
LMR Partners
London,
United Kingdom
|
-$33K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$28.4K |
SLS Hedge Fund Activity: Q3 2017 in Review
28 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in SELLAS Life Sciences (SLS) for Q3 2017, worth a combined $2.68M — down 41% from $4.57M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of SLS and 5 opened new positions — a net loss of 5 holders — while 8 trimmed existing stakes and 6 added.
The largest buyer was Renaissance Technologies, adding an estimated $242K. The largest seller was Element Capital Management, exiting entirely with an estimated $93K sold.
- 28 institutional investors held SELLAS Life Sciences (SLS) as of Q3 2017, down from 34 in Q2 2017.
- Funds reported $2.68M of SELLAS Life Sciences stock for Q3 2017, down 41% quarter-over-quarter.
- 5 funds opened new SELLAS Life Sciences positions in Q3 2017 and 10 closed out, a net change of -5 holders.
- The largest SELLAS Life Sciences buyer in Q3 2017 was Renaissance Technologies, an estimated $242K added.
- The largest SELLAS Life Sciences seller in Q3 2017 was Element Capital Management, an estimated $93K sold.
Based on aggregated 13F filings for Q3 2017.